APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pulmonary Arterial Hypertension (PAH) Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Pulmonary Arterial Hypertension (PAH) Drugs Market Analysis and Forecast 2026-2032

26 December 2025191 pages

Choose your research edition.

Industry ResearchPulmonary Arterial Hypertension (PAH) Drugs Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Pulmonary Arterial Hypertension (PAH) Drugs Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Pulmonary Arterial Hypertension (PAH) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pulmonary Arterial Hypertension (PAH) Drugs Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Pulmonary Arterial Hypertension (PAH) Drugs Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Pulmonary Arterial Hypertension (PAH) Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Pulmonary Arterial Hypertension (PAH) Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Pulmonary Arterial Hypertension (PAH) Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Pulmonary Arterial Hypertension (PAH) Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Pulmonary Arterial Hypertension (PAH) Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Pulmonary Arterial Hypertension (PAH) Drugs include Actelion Pharmaceuticals, Aires Pharmaceuticals, Arena Pharmaceuticals, AstraZeneca, Berlin Cures, Daiichi Sankyo, Eiger BioPharmaceuticals, Glaxosmithkline and Northern Therapeutics, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Pulmonary Arterial Hypertension (PAH) Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Pulmonary Arterial Hypertension (PAH) Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Pulmonary Arterial Hypertension (PAH) Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Pulmonary Arterial Hypertension (PAH) Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Pulmonary Arterial Hypertension (PAH) Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Pulmonary Arterial Hypertension (PAH) Drugs sales, projected growth trends, production technology, application and end-user industry.

Pulmonary Arterial Hypertension (PAH) Drugs Segment by Company

Actelion Pharmaceuticals

Aires Pharmaceuticals

Arena Pharmaceuticals

AstraZeneca

Berlin Cures

Daiichi Sankyo

Eiger BioPharmaceuticals

Glaxosmithkline

Northern Therapeutics

Reata Pharmaceuticals

United Therapeutics

Bayer Healthcare

Pfizer

Merck

Novartis

Pulmonary Arterial Hypertension (PAH) Drugs Segment by Type

Injectables

Inhalation

Oral Administration

Pulmonary Arterial Hypertension (PAH) Drugs Segment by Application

Hospitals

Clinics

Other

Pulmonary Arterial Hypertension (PAH) Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pulmonary Arterial Hypertension (PAH) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pulmonary Arterial Hypertension (PAH) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pulmonary Arterial Hypertension (PAH) Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Pulmonary Arterial Hypertension (PAH) Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Pulmonary Arterial Hypertension (PAH) Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pulmonary Arterial Hypertension (PAH) Drugs sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Injectables Major Manufacturers Table 3. Inhalation Major Manufacturers Table 4. Oral Administration Major Manufacturers Table 5. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospitals Major Manufacturers Table 7. Clinics Major Manufacturers Table 8. Other Major Manufacturers Table 9. Pulmonary Arterial Hypertension (PAH) Drugs Industry Trends Table 10. Pulmonary Arterial Hypertension (PAH) Drugs Industry Drivers Table 11. Pulmonary Arterial Hypertension (PAH) Drugs Industry Opportunities and Challenges Table 12. Pulmonary Arterial Hypertension (PAH) Drugs Industry Restraints Table 13. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 14. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region (2021-2026) & (US$ Million) Table 15. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region (2027-2032) & (US$ Million) Table 16. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Region (2021-2026) Table 17. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Region (2027-2032) Table 18. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (W Pcs) Table 19. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region (2021-2026) & (W Pcs) Table 20. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region (2027-2032) & (W Pcs) Table 21. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Region (2021-2026) Table 22. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Region (2027-2032) Table 23. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Manufacturers (2021-2026) Table 25. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Manufacturers (2021-2026) Table 27. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Price (US$/Pcs) of Manufacturers (2021-2026) Table 28. Global Pulmonary Arterial Hypertension (PAH) Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 29. Global Pulmonary Arterial Hypertension (PAH) Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 30. Global Pulmonary Arterial Hypertension (PAH) Drugs Manufacturers, Product Type & Application Table 31. Global Pulmonary Arterial Hypertension (PAH) Drugs Manufacturers' Establishment Date Table 32. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 33. Global Pulmonary Arterial Hypertension (PAH) Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 34. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 36. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 37. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Type (2021-2026) Table 38. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Type (2027-2032) Table 39. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type 2021 VS 2025 VS 2032 (W Pcs) Table 40. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2021-2026) & (W Pcs) Table 41. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2027-2032) & (W Pcs) Table 42. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2021-2026) Table 43. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2027-2032) Table 44. Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Type (2021-2026) & (US$/Pcs) Table 45. Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Type (2027-2032) & (US$/Pcs) Table 46. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 48. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 49. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Application (2021-2026) Table 50. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Application (2027-2032) Table 51. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application 2021 VS 2025 VS 2032 (W Pcs) Table 52. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2021-2026) & (W Pcs) Table 53. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2027-2032) & (W Pcs) Table 54. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2021-2026) Table 55. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2027-2032) Table 56. Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Application (2021-2026) & (US$/Pcs) Table 57. Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Application (2027-2032) & (US$/Pcs) Table 58. Actelion Pharmaceuticals Company Information Table 59. Actelion Pharmaceuticals Business Overview Table 60. Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 61. Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 62. Actelion Pharmaceuticals Recent Development Table 63. Aires Pharmaceuticals Company Information Table 64. Aires Pharmaceuticals Business Overview Table 65. Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 66. Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 67. Aires Pharmaceuticals Recent Development Table 68. Arena Pharmaceuticals Company Information Table 69. Arena Pharmaceuticals Business Overview Table 70. Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 71. Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 72. Arena Pharmaceuticals Recent Development Table 73. AstraZeneca Company Information Table 74. AstraZeneca Business Overview Table 75. AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 76. AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 77. AstraZeneca Recent Development Table 78. Berlin Cures Company Information Table 79. Berlin Cures Business Overview Table 80. Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 81. Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 82. Berlin Cures Recent Development Table 83. Daiichi Sankyo Company Information Table 84. Daiichi Sankyo Business Overview Table 85. Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 86. Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 87. Daiichi Sankyo Recent Development Table 88. Eiger BioPharmaceuticals Company Information Table 89. Eiger BioPharmaceuticals Business Overview Table 90. Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 91. Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 92. Eiger BioPharmaceuticals Recent Development Table 93. Glaxosmithkline Company Information Table 94. Glaxosmithkline Business Overview Table 95. Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 96. Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 97. Glaxosmithkline Recent Development Table 98. Northern Therapeutics Company Information Table 99. Northern Therapeutics Business Overview Table 100. Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 101. Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 102. Northern Therapeutics Recent Development Table 103. Reata Pharmaceuticals Company Information Table 104. Reata Pharmaceuticals Business Overview Table 105. Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 106. Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 107. Reata Pharmaceuticals Recent Development Table 108. United Therapeutics Company Information Table 109. United Therapeutics Business Overview Table 110. United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 111. United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 112. United Therapeutics Recent Development Table 113. Bayer Healthcare Company Information Table 114. Bayer Healthcare Business Overview Table 115. Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 116. Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 117. Bayer Healthcare Recent Development Table 118. Pfizer Company Information Table 119. Pfizer Business Overview Table 120. Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 121. Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 122. Pfizer Recent Development Table 123. Merck Company Information Table 124. Merck Business Overview Table 125. Merck Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 126. Merck Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 127. Merck Recent Development Table 128. Novartis Company Information Table 129. Novartis Business Overview Table 130. Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 131. Novartis Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 132. Novartis Recent Development Table 133. North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 134. North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 135. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2021-2026) & (W Pcs) Table 136. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2027-2032) & (W Pcs) Table 137. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Price by Type (2021-2026) & (US$/Pcs) Table 138. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Price by Type (2027-2032) & (US$/Pcs) Table 139. North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 140. North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 141. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2021-2026) & (W Pcs) Table 142. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2027-2032) & (W Pcs) Table 143. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Price by Application (2021-2026) & (US$/Pcs) Table 144. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Price by Application (2027-2032) & (US$/Pcs) Table 145. North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 146. North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 147. North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 148. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2021 VS 2025 VS 2032) & (W Pcs) Table 149. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2021-2026) & (W Pcs) Table 150. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2027-2032) & (W Pcs) Table 151. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Price by Country (2021-2026) & (US$/Pcs) Table 152. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Price by Country (2027-2032) & (US$/Pcs) Table 153. United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2021-2032) & (US$ Million) Table 154. Canada Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2021-2032) & (US$ Million) Table 155. Mexico Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2021-2032) & (US$ Million) Table 156. Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 157. Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 158. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2021-2026) & (W Pcs) Table 159. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2027-2032) & (W Pcs) Table 160. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Price by Type (2021-2026) & (US$/Pcs) Table 161. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Price by Type (2027-2032) & (US$/Pcs) Table 162. Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 163. Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 164. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2021-2026) & (W Pcs) Table 165. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2027-2032) & (W Pcs) Table 166. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Price by Application (2021-2026) & (US$/Pcs) Table 167. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Price by Application (2027-2032) & (US$/Pcs) Table 168. Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 169. Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 170. Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 171. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2021 VS 2025 VS 2032) & (W Pcs) Table 172. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2021-2026) & (W Pcs) Table 173. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2027-2032) & (W Pcs) Table 174. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Price by Country (2021-2026) & (US$/Pcs) Table 175. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Price by Country (2027-2032) & (US$/Pcs) Table 176. Germany Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2021-2032) & (US$ Million) Table 177. France Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2021-2032) & (US$ Million) Table 178. U.K. Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2021-2032) & (US$ Million) Table 179. Italy Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2021-2032) & (US$ Million) Table 180. Russia Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2021-2032) & (US$ Million) Table 181. Spain Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2021-2032) & (US$ Million) Table 182. Netherlands Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2021-2032) & (US$ Million) Table 183. Switzerland Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2021-2032) & (US$ Million) Table 184. Sweden Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2021-2032) & (US$ Million) Table 185. Poland Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2021-2032) & (US$ Million) Table 186. China Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 187. China Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 188. China Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2021-2026) & (W Pcs) Table 189. China Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2027-2032) & (W Pcs) Table 190. China Pulmonary Arterial Hypertension (PAH) Drugs Sales Price by Type (2021-2026) & (US$/Pcs) Table 191. China Pulmonary Arterial Hypertension (PAH) Drugs Sales Price by Type (2027-2032) & (US$/Pcs) Table 192. China Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 193. China Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 194. China Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2021-2026) & (W Pcs) Table 195. China Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2027-2032) & (W Pcs) Table 196. China Pulmonary Arterial Hypertension (PAH) Drugs Sales Price by Application (2021-2026) & (US$/Pcs) Table 197. China Pulmonary Arterial Hypertension (PAH) Drugs Sales Price by Application (2027-2032) & (US$/Pcs) Table 198. Asia Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 199. Asia Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 200. Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2021-2026) & (W Pcs) Table 201. Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2027-2032) & (W Pcs) Table 202. Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales Price by Type (2021-2026) & (US$/Pcs) Table 203. Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales Price by Type (2027-2032) & (US$/Pcs) Table 204. Asia Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 205. Asia Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 206. Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2021-2026) & (W Pcs) Table 207. Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2027-2032) & (W Pcs) Table 208. Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales Price by Application (2021-2026) & (US$/Pcs) Table 209. Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales Price by Application (2027-2032) & (US$/Pcs) Table 210. Asia Pulmonary Arterial Hypertension (PAH) Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 211. Asia Pulmonary Arterial Hypertension (PAH) Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 212. Asia Pulmonary Arterial Hypertension (PAH) Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 213. Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2021 VS 2025 VS 2032) & (W Pcs) Table 214. Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2021-2026) & (W Pcs) Table 215. Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2027-2032) & (W Pcs) Table 216. Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales Price by Country (2021-2026) & (US$/Pcs) Table 217. Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales Price by Country (2027-2032) & (US$/Pcs) Table 218. Japan Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2021-2032) & (US$ Million) Table 219. South Korea Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2021-2032) & (US$ Million) Table 220. India Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2021-2032) & (US$ Million) Table 221. Australia Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2021-2032) & (US$ Million) Table 222. Taiwan Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2021-2032) & (US$ Million) Table 223. Southeast Asia Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2021-2032) & (US$ Million) Table 224. SAMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 225. SAMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 226. SAMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2021-2026) & (W Pcs) Table 227. SAMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2027-2032) & (W Pcs) Table 228. SAMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Price by Type (2021-2026) & (US$/Pcs) Table 229. SAMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Price by Type (2027-2032) & (US$/Pcs) Table 230. SAMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 231. SAMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 232. SAMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2021-2026) & (W Pcs) Table 233. SAMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2027-2032) & (W Pcs) Table 234. SAMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Price by Application (2021-2026) & (US$/Pcs) Table 235. SAMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Price by Application (2027-2032) & (US$/Pcs) Table 236. SAMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 237. SAMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 238. SAMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 239. SAMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2021 VS 2025 VS 2032) & (W Pcs) Table 240. SAMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2021-2026) & (W Pcs) Table 241. SAMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2027-2032) & (W Pcs) Table 242. SAMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Price by Country (2021-2026) & (US$/Pcs) Table 243. SAMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Price by Country (2027-2032) & (US$/Pcs) Table 244. Brazil Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2021-2032) & (US$ Million) Table 245. Argentina Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2021-2032) & (US$ Million) Table 246. Chile Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2021-2032) & (US$ Million) Table 247. Colombia Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2021-2032) & (US$ Million) Table 248. Peru Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2021-2032) & (US$ Million) Table 249. Saudi Arabia Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2021-2032) & (US$ Million) Table 250. Israel Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2021-2032) & (US$ Million) Table 251. UAE Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2021-2032) & (US$ Million) Table 252. Turkey Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2021-2032) & (US$ Million) Table 253. Iran Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2021-2032) & (US$ Million) Table 254. Egypt Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2021-2032) & (US$ Million) Table 255. Key Raw Materials Table 256. Raw Materials Key Suppliers Table 257. Pulmonary Arterial Hypertension (PAH) Drugs Distributors List Table 258. Pulmonary Arterial Hypertension (PAH) Drugs Customers List Table 259. Research Programs/Design for This Report Table 260. Authors List of This Report Table 261. Secondary Sources Table 262. Primary Sources List of Figures Figure 1. Pulmonary Arterial Hypertension (PAH) Drugs Image Figure 2. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Injectables Image Figure 5. Inhalation Image Figure 6. Oral Administration Image Figure 7. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospitals Image Figure 10. Clinics Image Figure 11. Other Image Figure 12. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2021-2032) & (US$ Million) Figure 14. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 15. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Region: 2025 Versus 2032 Figure 16. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Region (2021-2032) Figure 17. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales (2021-2032) & (W Pcs) Figure 18. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region: 2021 VS 2025 VS 2032 (W Pcs) Figure 19. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Region (2021-2032) Figure 20. US & Canada & Mexico Pulmonary Arterial Hypertension (PAH) Drugs Sales YoY (2021-2032) & (W Pcs) Figure 21. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales YoY (2021-2032) & (W Pcs) Figure 22. China Pulmonary Arterial Hypertension (PAH) Drugs Sales YoY (2021-2032) & (W Pcs) Figure 23. Asia (Excluding China) Pulmonary Arterial Hypertension (PAH) Drugs Sales YoY (2021-2032) & (W Pcs) Figure 24. South America, Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales YoY (2021-2032) & (W Pcs) Figure 25. Global Pulmonary Arterial Hypertension (PAH) Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 26. Global Pulmonary Arterial Hypertension (PAH) Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 27. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 28. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 30. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Type (2021-2032) Figure 31. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2021 VS 2025 VS 2032) & (W Pcs) Figure 32. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2021-2032) Figure 34. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 35. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 36. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Application (2021-2032) Figure 37. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2021 VS 2025 VS 2032) & (W Pcs) Figure 38. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2021-2032) Figure 40. North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Type (2021-2032) Figure 41. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Type (2021-2032) Figure 42. North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Application (2021-2032) Figure 43. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Application (2021-2032) Figure 44. North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Country (2021-2032) Figure 45. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Country (2021-2032) Figure 46. Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Type (2021-2032) Figure 47. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Type (2021-2032) Figure 48. Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Application (2021-2032) Figure 49. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Application (2021-2032) Figure 50. Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Country (2021-2032) Figure 51. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Country (2021-2032) Figure 52. China Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Type (2021-2032) Figure 53. China Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Type (2021-2032) Figure 54. China Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Application (2021-2032) Figure 55. China Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Application (2021-2032) Figure 56. Asia Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Type (2021-2032) Figure 57. Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Type (2021-2032) Figure 58. Asia Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Application (2021-2032) Figure 59. Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Application (2021-2032) Figure 60. Asia Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Country (2021-2032) Figure 61. Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Country (2021-2032) Figure 62. SAMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Type (2021-2032) Figure 63. SAMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Type (2021-2032) Figure 64. SAMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Application (2021-2032) Figure 65. SAMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Application (2021-2032) Figure 66. SAMEA Pulmonary Arterial Hype

Scope & coverage.

Types
  • Injectables
  • Inhalation
  • Oral Administration
Applications
  • Hospitals
  • Clinics
  • Other
Companies covered
  • Actelion Pharmaceuticals
  • Aires Pharmaceuticals
  • Arena Pharmaceuticals
  • AstraZeneca
  • Berlin Cures
  • Daiichi Sankyo
  • Eiger BioPharmaceuticals
  • Glaxosmithkline
  • Northern Therapeutics
  • Reata Pharmaceuticals
  • United Therapeutics
  • Bayer Healthcare
  • Pfizer
  • Merck
  • Novartis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Pulmonary Arterial Hypertension (PAH) Drugs Market by Type
  3. 1.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Injectables
  5. 1.2.3 Inhalation
  6. 1.2.4 Oral Administration
  7. 1.3 Pulmonary Arterial Hypertension (PAH) Drugs Market by Application
  8. 1.3.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospitals
  10. 1.3.3 Clinics
  11. 1.3.4 Other
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Pulmonary Arterial Hypertension (PAH) Drugs Market Dynamics
  1. 2.1 Pulmonary Arterial Hypertension (PAH) Drugs Industry Trends
  2. 2.2 Pulmonary Arterial Hypertension (PAH) Drugs Industry Drivers
  3. 2.3 Pulmonary Arterial Hypertension (PAH) Drugs Industry Opportunities and Challenges
  4. 2.4 Pulmonary Arterial Hypertension (PAH) Drugs Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region
  3. 3.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region (2021-2026)
  5. 3.2.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region (2027-2032)
  6. 3.2.4 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region
  9. 3.4.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region (2021-2026)
  11. 3.4.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region (2027-2032)
  12. 3.4.4 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Manufacturers
  2. 4.1.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Manufacturers
  6. 4.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Pulmonary Arterial Hypertension (PAH) Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Pulmonary Arterial Hypertension (PAH) Drugs Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Pulmonary Arterial Hypertension (PAH) Drugs Manufacturers, Product Type & Application
  13. 4.7 Global Pulmonary Arterial Hypertension (PAH) Drugs Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market CR5 and HHI
  16. 4.8.2 2025 Pulmonary Arterial Hypertension (PAH) Drugs Tier 1, Tier 2, and Tier 3
5 Pulmonary Arterial Hypertension (PAH) Drugs Market by Type
  1. 5.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type
  2. 5.1.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type
  6. 5.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2021-2032) & (W Pcs)
  8. 5.2.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2021-2032)
  9. 5.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Type
6 Pulmonary Arterial Hypertension (PAH) Drugs Market by Application
  1. 6.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application
  2. 6.1.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application
  6. 6.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2021-2032) & (W Pcs)
  8. 6.2.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2021-2032)
  9. 6.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Application
7 Company Profiles
  1. 7.1 Actelion Pharmaceuticals
  2. 7.1.1 Actelion Pharmaceuticals Company Information
  3. 7.1.2 Actelion Pharmaceuticals Business Overview
  4. 7.1.3 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  6. 7.1.5 Actelion Pharmaceuticals Recent Developments
  7. 7.2 Aires Pharmaceuticals
  8. 7.2.1 Aires Pharmaceuticals Company Information
  9. 7.2.2 Aires Pharmaceuticals Business Overview
  10. 7.2.3 Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  12. 7.2.5 Aires Pharmaceuticals Recent Developments
  13. 7.3 Arena Pharmaceuticals
  14. 7.3.1 Arena Pharmaceuticals Company Information
  15. 7.3.2 Arena Pharmaceuticals Business Overview
  16. 7.3.3 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  18. 7.3.5 Arena Pharmaceuticals Recent Developments
  19. 7.4 AstraZeneca
  20. 7.4.1 AstraZeneca Company Information
  21. 7.4.2 AstraZeneca Business Overview
  22. 7.4.3 AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  24. 7.4.5 AstraZeneca Recent Developments
  25. 7.5 Berlin Cures
  26. 7.5.1 Berlin Cures Company Information
  27. 7.5.2 Berlin Cures Business Overview
  28. 7.5.3 Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  30. 7.5.5 Berlin Cures Recent Developments
  31. 7.6 Daiichi Sankyo
  32. 7.6.1 Daiichi Sankyo Company Information
  33. 7.6.2 Daiichi Sankyo Business Overview
  34. 7.6.3 Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  36. 7.6.5 Daiichi Sankyo Recent Developments
  37. 7.7 Eiger BioPharmaceuticals
  38. 7.7.1 Eiger BioPharmaceuticals Company Information
  39. 7.7.2 Eiger BioPharmaceuticals Business Overview
  40. 7.7.3 Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  42. 7.7.5 Eiger BioPharmaceuticals Recent Developments
  43. 7.8 Glaxosmithkline
  44. 7.8.1 Glaxosmithkline Company Information
  45. 7.8.2 Glaxosmithkline Business Overview
  46. 7.8.3 Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  48. 7.8.5 Glaxosmithkline Recent Developments
  49. 7.9 Northern Therapeutics
  50. 7.9.1 Northern Therapeutics Company Information
  51. 7.9.2 Northern Therapeutics Business Overview
  52. 7.9.3 Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  54. 7.9.5 Northern Therapeutics Recent Developments
  55. 7.10 Reata Pharmaceuticals
  56. 7.10.1 Reata Pharmaceuticals Company Information
  57. 7.10.2 Reata Pharmaceuticals Business Overview
  58. 7.10.3 Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  60. 7.10.5 Reata Pharmaceuticals Recent Developments
  61. 7.11 United Therapeutics
  62. 7.11.1 United Therapeutics Company Information
  63. 7.11.2 United Therapeutics Business Overview
  64. 7.11.3 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  66. 7.11.5 United Therapeutics Recent Developments
  67. 7.12 Bayer Healthcare
  68. 7.12.1 Bayer Healthcare Company Information
  69. 7.12.2 Bayer Healthcare Business Overview
  70. 7.12.3 Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  72. 7.12.5 Bayer Healthcare Recent Developments
  73. 7.13 Pfizer
  74. 7.13.1 Pfizer Company Information
  75. 7.13.2 Pfizer Business Overview
  76. 7.13.3 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  78. 7.13.5 Pfizer Recent Developments
  79. 7.14 Merck
  80. 7.14.1 Merck Company Information
  81. 7.14.2 Merck Business Overview
  82. 7.14.3 Merck Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Merck Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  84. 7.14.5 Merck Recent Developments
  85. 7.15 Novartis
  86. 7.15.1 Novartis Company Information
  87. 7.15.2 Novartis Business Overview
  88. 7.15.3 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  90. 7.15.5 Novartis Recent Developments
8 North America
  1. 8.1 North America Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Type
  2. 8.1.1 North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2021-2032)
  3. 8.1.2 North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2021-2032)
  4. 8.1.3 North America Pulmonary Arterial Hypertension (PAH) Drugs Price by Type (2021-2032)
  5. 8.2 North America Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Application
  6. 8.2.1 North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2021-2032)
  7. 8.2.2 North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2021-2032)
  8. 8.2.3 North America Pulmonary Arterial Hypertension (PAH) Drugs Price by Application (2021-2032)
  9. 8.3 North America Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country
  10. 8.3.1 North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Pulmonary Arterial Hypertension (PAH) Drugs Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Type
  2. 9.1.1 Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2021-2032)
  3. 9.1.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2021-2032)
  4. 9.1.3 Europe Pulmonary Arterial Hypertension (PAH) Drugs Price by Type (2021-2032)
  5. 9.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Application
  6. 9.2.1 Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2021-2032)
  7. 9.2.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2021-2032)
  8. 9.2.3 Europe Pulmonary Arterial Hypertension (PAH) Drugs Price by Application (2021-2032)
  9. 9.3 Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country
  10. 9.3.1 Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Pulmonary Arterial Hypertension (PAH) Drugs Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Type
  2. 10.1.1 China Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2021-2032)
  3. 10.1.2 China Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2021-2032)
  4. 10.1.3 China Pulmonary Arterial Hypertension (PAH) Drugs Price by Type (2021-2032)
  5. 10.2 China Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Application
  6. 10.2.1 China Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2021-2032)
  7. 10.2.2 China Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2021-2032)
  8. 10.2.3 China Pulmonary Arterial Hypertension (PAH) Drugs Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Type
  2. 11.1.1 Asia Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2021-2032)
  3. 11.1.2 Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2021-2032)
  4. 11.1.3 Asia Pulmonary Arterial Hypertension (PAH) Drugs Price by Type (2021-2032)
  5. 11.2 Asia Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Application
  6. 11.2.1 Asia Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2021-2032)
  7. 11.2.2 Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2021-2032)
  8. 11.2.3 Asia Pulmonary Arterial Hypertension (PAH) Drugs Price by Application (2021-2032)
  9. 11.3 Asia Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country
  10. 11.3.1 Asia Pulmonary Arterial Hypertension (PAH) Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Pulmonary Arterial Hypertension (PAH) Drugs Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Type
  2. 12.1.1 SAMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Pulmonary Arterial Hypertension (PAH) Drugs Price by Type (2021-2032)
  5. 12.2 SAMEA Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Application
  6. 12.2.1 SAMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Pulmonary Arterial Hypertension (PAH) Drugs Price by Application (2021-2032)
  9. 12.3 SAMEA Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country
  10. 12.3.1 SAMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Pulmonary Arterial Hypertension (PAH) Drugs Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Pulmonary Arterial Hypertension (PAH) Drugs Value Chain Analysis
  2. 13.1.1 Pulmonary Arterial Hypertension (PAH) Drugs Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Pulmonary Arterial Hypertension (PAH) Drugs Production Mode & Process
  6. 13.2 Pulmonary Arterial Hypertension (PAH) Drugs Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Pulmonary Arterial Hypertension (PAH) Drugs Distributors
  9. 13.2.3 Pulmonary Arterial Hypertension (PAH) Drugs Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst